vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and Porch Group, Inc. (PRCH). Click either name above to swap in a different company.
ADMA BIOLOGICS, INC. is the larger business by last-quarter revenue ($139.2M vs $121.1M, roughly 1.1× Porch Group, Inc.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs -3.9%, a 39.4% gap on every dollar of revenue. On growth, Porch Group, Inc. posted the faster year-over-year revenue change (100.0% vs 18.4%). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 26.4%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Porch is a website that tries to connect homeowners with local home improvement contractors. The site features advice articles, cost guide, and online booking for over 160 home projects.
ADMA vs PRCH — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $121.1M |
| Net Profit | $49.4M | $-4.7M |
| Gross Margin | 63.8% | 52.7% |
| Operating Margin | 45.1% | 34.7% |
| Net Margin | 35.5% | -3.9% |
| Revenue YoY | 18.4% | 100.0% |
| Net Profit YoY | -55.9% | 2.0% |
| EPS (diluted) | $0.20 | $-0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $121.1M | ||
| Q4 25 | $139.2M | $112.3M | ||
| Q3 25 | $134.2M | $115.1M | ||
| Q2 25 | $122.0M | $107.0M | ||
| Q1 25 | $114.8M | $84.5M | ||
| Q4 24 | $117.5M | $75.3M | ||
| Q3 24 | $119.8M | $77.7M | ||
| Q2 24 | $107.2M | $75.9M |
| Q1 26 | — | $-4.7M | ||
| Q4 25 | $49.4M | $-3.5M | ||
| Q3 25 | $36.4M | $-10.9M | ||
| Q2 25 | $34.2M | $2.6M | ||
| Q1 25 | $26.9M | $8.4M | ||
| Q4 24 | $111.9M | $30.5M | ||
| Q3 24 | $35.9M | $14.4M | ||
| Q2 24 | $32.1M | $-64.3M |
| Q1 26 | — | 52.7% | ||
| Q4 25 | 63.8% | 99.5% | ||
| Q3 25 | 56.3% | 75.6% | ||
| Q2 25 | 55.1% | 70.9% | ||
| Q1 25 | 53.2% | 77.4% | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | 79.4% | ||
| Q2 24 | 53.6% | 22.1% |
| Q1 26 | — | 34.7% | ||
| Q4 25 | 45.1% | 14.7% | ||
| Q3 25 | 38.0% | 14.2% | ||
| Q2 25 | 35.1% | 4.7% | ||
| Q1 25 | 30.4% | -1.5% | ||
| Q4 24 | 32.6% | 33.3% | ||
| Q3 24 | 33.1% | -3.2% | ||
| Q2 24 | 36.6% | -69.2% |
| Q1 26 | — | -3.9% | ||
| Q4 25 | 35.5% | -3.1% | ||
| Q3 25 | 27.1% | -9.4% | ||
| Q2 25 | 28.1% | 2.4% | ||
| Q1 25 | 23.4% | 9.9% | ||
| Q4 24 | 95.2% | 40.5% | ||
| Q3 24 | 30.0% | 18.5% | ||
| Q2 24 | 29.9% | -84.8% |
| Q1 26 | — | $-0.04 | ||
| Q4 25 | $0.20 | $0.00 | ||
| Q3 25 | $0.15 | $-0.10 | ||
| Q2 25 | $0.14 | $0.00 | ||
| Q1 25 | $0.11 | $0.07 | ||
| Q4 24 | $0.45 | $0.34 | ||
| Q3 24 | $0.15 | $0.12 | ||
| Q2 24 | $0.13 | $-0.65 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $68.4M |
| Total DebtLower is stronger | $72.1M | $391.3M |
| Stockholders' EquityBook value | $477.3M | $26.3M |
| Total Assets | $624.2M | $806.6M |
| Debt / EquityLower = less leverage | 0.15× | 14.87× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $68.4M | ||
| Q4 25 | $87.6M | $57.3M | ||
| Q3 25 | $61.4M | $85.0M | ||
| Q2 25 | $90.3M | $79.8M | ||
| Q1 25 | $71.6M | $70.4M | ||
| Q4 24 | $103.1M | $191.7M | ||
| Q3 24 | $86.7M | $238.6M | ||
| Q2 24 | $88.2M | $308.4M |
| Q1 26 | — | $391.3M | ||
| Q4 25 | $72.1M | $392.8M | ||
| Q3 25 | $72.4M | $387.1M | ||
| Q2 25 | — | $394.1M | ||
| Q1 25 | — | $409.2M | ||
| Q4 24 | $72.3M | $403.9M | ||
| Q3 24 | — | $399.0M | ||
| Q2 24 | — | $436.8M |
| Q1 26 | — | $26.3M | ||
| Q4 25 | $477.3M | $-24.6M | ||
| Q3 25 | $431.2M | $-27.9M | ||
| Q2 25 | $398.3M | $-29.3M | ||
| Q1 25 | $373.4M | $-52.4M | ||
| Q4 24 | $349.0M | $-43.2M | ||
| Q3 24 | $231.9M | $-77.0M | ||
| Q2 24 | $188.3M | $-101.9M |
| Q1 26 | — | $806.6M | ||
| Q4 25 | $624.2M | $797.4M | ||
| Q3 25 | $568.7M | $787.7M | ||
| Q2 25 | $558.4M | $770.7M | ||
| Q1 25 | $510.6M | $802.3M | ||
| Q4 24 | $488.7M | $814.0M | ||
| Q3 24 | $390.6M | $867.3M | ||
| Q2 24 | $376.4M | $876.1M |
| Q1 26 | — | 14.87× | ||
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | — |
| Free Cash FlowOCF − Capex | $34.6M | — |
| FCF MarginFCF / Revenue | 24.8% | — |
| Capex IntensityCapex / Revenue | 0.8% | — |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $35.6M | $1.2M | ||
| Q3 25 | $13.3M | $40.8M | ||
| Q2 25 | $21.1M | $35.6M | ||
| Q1 25 | $-19.7M | $-11.2M | ||
| Q4 24 | $50.2M | $-26.6M | ||
| Q3 24 | $25.0M | $12.4M | ||
| Q2 24 | $45.6M | $-26.0M |
| Q1 26 | — | — | ||
| Q4 25 | $34.6M | $1.1M | ||
| Q3 25 | $-1.1M | $40.7M | ||
| Q2 25 | $18.7M | $35.4M | ||
| Q1 25 | $-24.4M | $-11.2M | ||
| Q4 24 | $47.5M | $-26.8M | ||
| Q3 24 | $24.0M | $12.2M | ||
| Q2 24 | $43.6M | $-26.0M |
| Q1 26 | — | — | ||
| Q4 25 | 24.8% | 1.0% | ||
| Q3 25 | -0.8% | 35.4% | ||
| Q2 25 | 15.3% | 33.0% | ||
| Q1 25 | -21.2% | -13.3% | ||
| Q4 24 | 40.4% | -35.6% | ||
| Q3 24 | 20.0% | 15.7% | ||
| Q2 24 | 40.7% | -34.3% |
| Q1 26 | — | — | ||
| Q4 25 | 0.8% | 0.1% | ||
| Q3 25 | 10.7% | 0.1% | ||
| Q2 25 | 2.0% | 0.2% | ||
| Q1 25 | 4.1% | 0.1% | ||
| Q4 24 | 2.3% | 0.3% | ||
| Q3 24 | 0.9% | 0.3% | ||
| Q2 24 | 1.9% | 0.1% |
| Q1 26 | — | — | ||
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.62× | 13.79× | ||
| Q1 25 | -0.73× | -1.33× | ||
| Q4 24 | 0.45× | -0.87× | ||
| Q3 24 | 0.70× | 0.86× | ||
| Q2 24 | 1.42× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
PRCH
Segment breakdown not available.
